• +1-646-491-9876
    • +91-20-67278686

    Search

    Progressive Supranuclear Palsy-Pipeline Review H1 2017

    Progressive Supranuclear Palsy-Pipeline Review H1 2017

    • Report Code ID: RW0001834402
    • Category Pharmaceuticals
    • No. of Pages 75
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Progressive Supranuclear Palsy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2017, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.

    Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 4, 1, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Progressive Supranuclear Palsy - Overview
    Progressive Supranuclear Palsy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Progressive Supranuclear Palsy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
    AB Science SA
    AbbVie Inc
    AlzProtect SAS
    Asceneuron SA
    Bristol-Myers Squibb Company
    Cortice Biosciences Inc
    Intellect Neurosciences Inc
    K-Stemcell Co Ltd
    Merck & Co Inc
    Prana Biotechnology Ltd
    TauRx Therapeutics Ltd
    Progressive Supranuclear Palsy - Drug Profiles
    ABBV-8E12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASN-120290 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZP-2006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986168 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DC-TAB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DPC-016 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    masitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-8719 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PBT-434 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TauC-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tolfenamic acid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPI-287 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TRx-0237 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Progressive Supranuclear Palsy - Dormant Projects
    Progressive Supranuclear Palsy - Product Development Milestones
    Featured News & Press Releases
    May 04, 2017: AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)
    Apr 04, 2017: Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor
    Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
    Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy
    Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy
    Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Progressive Supranuclear Palsy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Progressive Supranuclear Palsy - Pipeline by AB Science SA, H1 2017
    Progressive Supranuclear Palsy - Pipeline by AbbVie Inc, H1 2017
    Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Intellect Neurosciences Inc, H1 2017
    Progressive Supranuclear Palsy - Pipeline by K-Stemcell Co Ltd, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, H1 2017
    Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Ltd, H1 2017
    Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, H1 2017
    Progressive Supranuclear Palsy - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Progressive Supranuclear Palsy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AB Science SA
    AbbVie Inc
    AlzProtect SAS
    Asceneuron SA
    Bristol-Myers Squibb Company
    Cortice Biosciences Inc
    Intellect Neurosciences Inc
    K-Stemcell Co Ltd
    Merck & Co Inc
    Prana Biotechnology Ltd
    TauRx Therapeutics Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//progressive-supranuclear-palsy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//progressive-supranuclear-palsy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//progressive-supranuclear-palsy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments